Year-end Sale % OFF 
Abstract
BackgroundMultidrug resistant (MDR) bacteria are responsible for therapeutic failure and there is an urgent need for novels compounds efficient on them.MethodsEleven methanol extracts from seven Cameroonian medicinal plants were tested for their antibacterial activity using broth micro-dilution method against 36 MDR bacterial strains including Escherichia coli, Enterobacter aerogenes, Enterobacter cloacae, Klebsiella pneumoniae, Providencia stuartii, Pseudomonas aeruginosa and Staphylococcus aureus.ResultsEuphorbia prostrata extract was found active against all the 36 tested bacteria including Gram-negative phenotypes over-expressing efflux pumps such as P. aeruginosa PA124, E. aerogenes CM64 and E. coli AG102. E. prostrata had minimal inhibitory concentrations values between 128 and 256 µg/mL on 55.55% of the studied microorganisms. Other plants extract displayed selective antibacterial activity.ConclusionsResults obtained in this study highlight the antibacterial potential of the tested plants and the possible use of E. prostrata to combat bacterial infections including MDR phenotypes.
Highlights
Multidrug resistant (MDR) bacteria are responsible for therapeutic failure and there is an urgent need for novels compounds efficient on them
It appears that the plant extract from E. prostrata was active against all tested bacterial strains (36/36) with minimal inhibitory concentrations (MIC) between 128 and 256 μg/mL on 55.55% (20/36) of the studied microorganisms
Leaves extract of R. macrophylla were active against 83.33% (30/36) of the tested bacteria while only 3/36 (8.33%) of the studied bacteria were sensitive to the bark extract
Summary
Multidrug resistant (MDR) bacteria are responsible for therapeutic failure and there is an urgent need for novels compounds efficient on them. Bacterial multidrug-resistance is the ability of bacteria to grow in the presence of antibiotics at concentrations that were previously inhibitory. Treating infections caused by multidrug-resistant (MDR) bacteria is a challenge more and more difficult to solve within hospital units [1]. Patients infected by these bacteria stay for long time, which impacts on the cost of treatment. Faced with this crisis, it is important to develop new antibacterial molecules effective vis-à-vis of MDR bacteria and medicinal.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
